Doprokin 10 mg tablets help support the stomach and digestion, effectively relieving discomfort and unpleasant sensations.
International Nonproprietary Name (Active Substance): Domperidone
Each tablet contains 10 mg of domperidone.
Gastrointestinal motility regulator.
Nausea, vomiting, and dyspeptic symptoms caused by delayed gastric emptying, gastroesophageal reflux, or esophagitis (bloating, belching, flatulence, heartburn).
Functional or organic origin nausea and vomiting (including infections, dietary disturbances, chemical or radiotherapy).
Nausea and vomiting induced by dopamine agonists in Parkinson’s disease treatment (e.g., levodopa, bromocriptine).
Dosage Regimen:
Acute nausea or vomiting: 20 mg, 3–4 times daily and at bedtime.
Chronic dyspeptic symptoms: 10 mg, 3 times daily plus at bedtime.
If necessary, the dose may be doubled.
Acute nausea or vomiting: oral suspension, 5 mL per 10 kg body weight, 3–4 times daily and at bedtime.
Chronic dyspeptic symptoms: 2.5 mL per 10 kg body weight, 3 times daily plus at bedtime if needed.
Recommended to take before meals. Absorption may slow if taken after meals.
Tablets are not recommended for children under 5 years.
In patients with renal insufficiency, the dosing frequency should be reduced (see “Precautions”).
Hypersensitivity to domperidone or any tablet component.
Gastrointestinal bleeding.
Mechanical obstruction or perforation of intestines.
Prolactin-secreting pituitary tumor (prolactinoma).
When used with antacids or antisecretory drugs, domperidone should be taken after meals.
Regular monitoring is recommended during long-term therapy, especially in patients with liver or kidney disease.
Domperidone should be used cautiously in breastfeeding infants under close medical supervision due to immature metabolic and blood–brain barriers. Neurological side effects cannot be completely excluded in children under 1 year.
Caution in patients with hepatic insufficiency due to high liver metabolism of domperidone.
In severe renal insufficiency (serum creatinine >6 mg/100 mL), domperidone’s half-life may increase from 7.4 to 20.8 hours, though plasma concentrations remain lower than in healthy volunteers.
Minimal unchanged excretion by the kidneys; dose adjustment is generally not needed.
Repeated dosing should not exceed once or twice daily depending on severity; dose reduction may be required.
Teratogenic effects were not observed in animal studies with doses up to 160 mg/kg/day.
As with most medications, domperidone should be used in the first trimester only if therapeutic benefits outweigh risks.
